Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Shares Outstanding (Weighted Average) (2021 - 2025)

Historic Shares Outstanding (Weighted Average) for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to $93.3 million.

  • Amylyx Pharmaceuticals' Shares Outstanding (Weighted Average) rose 3707.0% to $93.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $93.3 million, marking a year-over-year increase of 3707.0%. This contributed to the annual value of $67.2 million for FY2023, which is 1493.94% up from last year.
  • Per Amylyx Pharmaceuticals' latest filing, its Shares Outstanding (Weighted Average) stood at $93.3 million for Q3 2025, which was up 3707.0% from $89.1 million recorded in Q2 2025.
  • Amylyx Pharmaceuticals' Shares Outstanding (Weighted Average)'s 5-year high stood at $93.3 million during Q3 2025, with a 5-year trough of $6.2 million in Q1 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $62.6 million (2022), whereas its average is $53.7 million.
  • As far as peak fluctuations go, Amylyx Pharmaceuticals' Shares Outstanding (Weighted Average) surged by 80576.48% in 2022, and later skyrocketed by 170.43% in 2024.
  • Over the past 5 years, Amylyx Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarter) stood at $6.6 million in 2021, then surged by 788.13% to $58.5 million in 2022, then rose by 14.94% to $67.2 million in 2023, then rose by 1.27% to $68.1 million in 2024, then soared by 37.07% to $93.3 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $93.3 million in Q3 2025, compared to $89.1 million in Q2 2025 and $85.7 million in Q1 2025.